TEC INHIBITORS- A NEW THERAPEUTIC FOR ALLERGIC DISEASES

Award Information
Agency:
Department of Health and Human Services
Amount:
$443,366.00
Program:
SBIR
Contract:
1R43AI051125-01
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2002
Phase:
Phase I
Agency Tracking Number:
AI051125
Solicitation Topic Code:
N/A
Small Business Information
ALLIMMUNE, LLC
ALLIMMUNE, LLC, 10355 SCIENCE CENTER DR, SAN DIEGO, CA, 92121
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 YUKO KAWAKAMI
 (858) 678-4634
 YUKO_KAWAKAMI@LIAI.ORG
Business Contact
 CHARLES CARPOWICH
Phone: (858) 558-3500
Email: SKIP_CARPOWICH@LIAI.ORG
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The incidence of allergic diseases such as atopic dermatitis (AD) has been dramatically increasing in the US and other industrialized countries for the past two decades. We and others have demonstrated that Tec family protein-tyrosine kinases have crucial roles in the activation of immune cells elicited by the engagement of antigen receptors or Fc receptors. As such, these kinases are supposed to play critical roles in the pathogenesis of AD and other allergic diseases that involve the activation of T and B lymphocytes, mast cells, and eosinophils. We recently identified a small-molecule compound, terreic acid (TA), as a selective inhibitor of Tec family kinases. In addition, we recently established highly efficient experimental conditions to rapidly induce skin lesions in AD-prone NC/Nga mice. Using this mouse model, we propose to explore whether TA or related compounds are therapeutically efficacious as a treatment of AD. Since we have a screening method for searching for Tec inhibitors whose usefulness has been proven, we will also expand our search for better compounds.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government